|
InvivoGen
human ace2 expressing a549 ![]() Human Ace2 Expressing A549, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-hACE2-TMPRSS2+Cells/pmc13303877-8-0-4 Average 99 stars, based on 1 article reviews
human ace2 expressing a549 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
human alveolar cells overexpressing ace2 ![]() Human Alveolar Cells Overexpressing Ace2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-hACE2-TMPRSS2+Cells/pmc13138061-582-4-9 Average 99 stars, based on 1 article reviews
human alveolar cells overexpressing ace2 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
human ace2 gene ![]() Human Ace2 Gene, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-hACE2-TMPRSS2+Cells/pm41666538-78-6-14 Average 99 stars, based on 1 article reviews
human ace2 gene - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 ace2 tmprss2 cells ![]() A549 Ace2 Tmprss2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-hACE2-TMPRSS2+Cells/pm41699454-129-0-8 Average 99 stars, based on 1 article reviews
a549 ace2 tmprss2 cells - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
a549 cells overexpressing ace2 ![]() A549 Cells Overexpressing Ace2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549/pmc12496188-265-3-22 Average 99 stars, based on 1 article reviews
a549 cells overexpressing ace2 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 ace2 tmprss2 ![]() A549 Ace2 Tmprss2, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-hACE2-TMPRSS2+Cells/pmc12423841-327-19-23 Average 99 stars, based on 1 article reviews
a549 ace2 tmprss2 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 dual ace2 tmprss2 cells ![]() A549 Dual Ace2 Tmprss2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549-ace2+cells/A549-Dual+hACE2-TMPRSS2+Cells/pm40586480-429-19-21 Average 99 stars, based on 1 article reviews
a549 dual ace2 tmprss2 cells - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
Journal: EMBO Reports
Article Title: TMPRSS2-induced Golgi disruption restricts the incorporation of virus envelope glycoproteins into virions
doi: 10.1038/s44319-026-00797-2
Figure Lengend Snippet: ( A ) Infectivity of CoV-2-S pseudotyped lentiviruses was determined in ACE2- and TMPRSS2-WT (TM2-WT), TMPRSS2-WT-mCherry- (TM2-WT-Cherry)-, TMPRSS2-dCT-mCherry- (TM2-dCT-Cherry)-, TMPRSS2-S441A-mCherry- (TM2-S441A-Cherry)-, and/or TMPRSS2-WT-Wasabi- (TM2-WT-Wasabi)-expressing 293T cells (left and middle, the quantified results from a representative experiment in the two experiments independently conducted are expressed as mean ± SEM, n = 6). Infectivity of CoV-2-S pseudotyped lentiviruses was determined in ACE2- and TM2-WT-Cherry (with indicated ratio of plasmids) expressing 293 T cells (right, the quantified results are expressed as mean ± SEM of three separate experiments, n = 3). Representative data from three independent experiments are shown. ( B ) Immunoblotting analysis of cell lysate from 293 T cells expressing CoV-2-S (left) or HIV-1 Env (right) and TM2-WT-mCherry (TM2-WT) or TM2-S441A-mCherry (TM2-S441A). The ratio of CoV-2-S2 or gp160 to beta-actin was calculated based on band density (the quantified results are expressed as mean ± SEM of three separate experiments, n = 3). ( C ) Fluorescence microscopy analysis of A549-ACE2 and A549-ACE2-TMPRSS2-mCherry- (TM2)-expressing cells. ( D ) Infectivity of SARS-CoV-2 spike protein pseudotyped lentiviruses in ACE2- or ACE2- and TM2-expressing A549 cells (the quantified results from a representative experiment in the two experiments independently conducted are expressed as mean ± SEM, n = 4). ( E ) q-PCR analysis for TMPRSS2 (TM2) mRNA in indicated cell lines (A549-ACE2-TM2: A549-ACE2 cells stably expressing TM2; 293T-TM2: 293T cells transiently expressing TM2) (the quantified results from a representative experiment in the two experiments independently conducted are expressed as mean ± SEM, n = 3). ( F ) q-PCR analysis for TM2 mRNA in original Caco-2 (Caco-2 WT) and TM2 knockdown Caco-2 (Caco-2 TM2-KD) cells (the quantified results from a representative experiment in the two experiments independently conducted are expressed as mean ± SEM, n = 3). Scale bars indicate 50 μm. The results of Student’s t tests are shown above the bars.
Article Snippet:
Techniques: Infection, Expressing, Western Blot, Fluorescence, Microscopy, Stable Transfection, Knockdown
Journal: EMBO Reports
Article Title: TMPRSS2-induced Golgi disruption restricts the incorporation of virus envelope glycoproteins into virions
doi: 10.1038/s44319-026-00797-2
Figure Lengend Snippet: ( A ) Experimental scheme and luciferase activity for the infectivity of SARS-CoV-2-Spike (CoV-2-S) or vesicular stomatitis virus G protein (VSV-G) pseudotyped lentiviruses produced in CD4-mCherry- (Control)-, TMPRSS2-mCherry- (TM2-WT)-, TMPRSS2-dCT-mCherry- (TM2-dCT)-, or TMPRSS2-S441A-mCherry-(TM2-S441A)-expressing 293T cells. The infectivity of pseudotyped lentiviruses (3 ng/well) normalized with p24 amount (left in panels, the quantified results are expressed as mean ± SEM of three separate experiments, n = 3) was determined in ACE2- and TM2-expressing 293T cells (right in panels, the quantified results from a representative experiment in the three experiments independently conducted are expressed as mean ± SEM, n = 6 for CoV-2-S, n = 5 for VSV-G). ( B ) Experimental scheme (left) and plaque-formation assay using Vero E6 TMPRSS2 cells to test the infectivity of SARS-CoV-2 produced in A549-ACE2 or A549-ACE2 stably expressing TMPRSS2 (A549-ACE2-TM2) cells (middle, n = 3). A549-ACE2 or A549-ACE2-TM2 cells infected with SARS-CoV-2. After normalization with SARS-CoV-2 nucleocapsid protein (NP, left in panels, the quantified results are expressed as mean ± SEM of four separate experiments, n = 4) amounts, the viruses were used in a plaque-formation assay using Vero E6 TMPRSS2 cells. Plaque-forming unit (pfu) per 80 pg of NP is shown (right, the quantified results from a representative experiment in the three experiments independently conducted are expressed as mean ± SEM, n = 6). ( C ) Experimental scheme (top) and luciferase activity for the infectivity of CoV-2-S pseudotyped lentiviruses produced in Calu-3 cells. Calu-3 cells transfected with CoV-2-S and lentiviral plasmids were treated with the indicated concentrations of nafamostat. After normalization with p24 amounts (bottom left, the quantified results are expressed as mean ± SEM of five separate experiments, n = 5), the pseudotyped lentiviruses (1.0 pg/well) were used to infect 293T cells expressing ACE2 (293T-ACE2), but not TM2, and the infectivity was determined as luciferase activity (bottom right, the quantified results from a representative experiment in the two experiments independently conducted are expressed as mean ± SEM, n = 5). ( D ) Immunoblotting analysis of CoV-2-S pseudotyped lentiviruses in 293T cells expressing CD4-mCherry- (Control)-, TM2-WT, TM2-dCT, or TM2-S441A. The ratio of CoV-2-S2 to p24 was calculated based on band density (right, the quantified results are expressed as mean ± SEM of three separate experiments, n = 3). The samples were obtained from the same experiment, and the gels and blots were processed in parallel. ( E ) Experimental scheme (left top) and plaque-formation assay of SARS-CoV-2 produced in nafamostat-treated Caco-2 cells (left bottom, n = 3). Caco-2 cells infected with SARS-CoV-2 were treated with the indicated concentrations of nafamostat. After the 96 hr culture, viruses were purified and normalized with SARS-CoV-2 NP amounts (right top, the quantified results are expressed as mean ± SEM of six separate experiments, n = 6), the viruses were used in a plaque-formation assay using Vero E6 TMPRSS2 cells. Plaque-forming unit (pfu) per 25 pg of NP is shown (right bottom, the quantified results from a representative experiment in the three experiments independently conducted are expressed as mean ± SEM, n = 8). ( F ) Experimental scheme (top) and plaque-formation assay (middle) of SARS-CoV-2 produced in Caco-2 cells ( n = 3). Original (WT) and TM2-knockdown (KD) Caco-2 cells were infected with SARS-CoV-2. After the 96 hr culture and normalization with SARS-CoV-2 NP amounts (bottom left, the quantified results are expressed as mean ± SEM of three separate experiments, n = 3), the viruses were used in a plaque-formation assay using Vero E6 TMPRSS2 cells. Plaque-forming unit (pfu) per 100 pg of NP is shown (right bottom, the quantified results from two experiments among the three experiments independently conducted are expressed as mean ± SEM, n = 6). The number in vectors indicates the ratio of plasmid used for transfection. The results of Student’s t tests are shown above the bars. .
Article Snippet:
Techniques: Luciferase, Activity Assay, Infection, Virus, Produced, Control, Expressing, Plaque Formation Assay, Stable Transfection, Transfection, Western Blot, Purification, Knockdown, Plasmid Preparation
Journal: iScience
Article Title: Evolution of the SARS-CoV-2 spike protein in utilizing host transmembrane serine proteases
doi: 10.1016/j.isci.2025.113318
Figure Lengend Snippet: SARS-CoV-2 replication in the presence of entry inhibitors A549 cells expressing both ACE2 and TMPRSS2 (A) or A549 cells expressing only ACE2 (B) were infected with a given isolate (at 800 TCID 50 per mL) for 2 h in the presence of 100 μM camostat (A), 10 μM E64D, or control PBS (A and B). At 96 h post inoculation, replication of SARS-CoV-2 was evaluated by RT-qPCR analysis, and the data are presented as RNA copy numbers/ml (mean ± SD). The p values were calculated by two-way ANOVA. (∗ p < 0.05; ns = not significant). n = 6 biological replicates.
Article Snippet: A549 (ATCC CCL-185),
Techniques: Expressing, Infection, Control, Quantitative RT-PCR
Journal: iScience
Article Title: Evolution of the SARS-CoV-2 spike protein in utilizing host transmembrane serine proteases
doi: 10.1016/j.isci.2025.113318
Figure Lengend Snippet: SARS-CoV-2 entry into A549 cells overexpressing ACE2 and different TTSPs (A) Lentiviral vectors were used to introduce matriptase (M), prostasin (P), hepsin (H) and Kallikrein 13 (KLK13) into A549 ACE2 cells. (A) After antibiotic selection, cells were lysed and proteins were resolved by SDS-PAGE and analyzed by Western blotting. Each protease was detected in A549 ACE2 cell lysates (50 μg of protein per lane) using anti-FLAG antibody (B) KLK13 mRNA was evaluated using PCR in positively transduced cells. Β-actin (ACTB) mRNA was used as an internal control. (B) Control A549 cells with ACE2 (Ctrl), A549 cells overexpressing both ACE2 and TMPRSS2 (TMPRSS2), ACE2 and KLK13 (KLK13), ACE2 and matriptase (Matriptase), ACE2 and prostasin (Prostasin), and ACE2 and hepsin (Hepsin) were transduced with HIV pseudoviruses decorated with VSV-G protein (VSV-G) or each SARS-CoV-2 variant S glycoprotein. After 72 h at 37°C, pseudovirus entry was measured by measurement of the luminescence signal in the cell lysates (relative light units [RLUs]/mL of lysate sample). The assay was performed twice, each time in triplicate ( N = 3), and average values with standard deviation are presented. (C) Control A549 cells with ACE2 (Ctrl), A549 cells overexpressing both ACE2 and TMPRSS2 (TMPRSS2), ACE2 and KLK13 (KLK13), ACE2 and matriptase (Matriptase), ACE2 and prostasin (Prostasin), and ACE2 and hepsin (Hepsin) were infected with a given isolate (at 800 TCID 50 per mL) for 2 h. At 96 h post inoculation, replication of SARS-CoV-2 was evaluated by RT-qPCR analysis, and the data are presented as RNA copy numbers/ml (mean ± SD). The p values were calculated by two-way ANOVA. (∗ p < 0.05). n = 6 biological replicates.
Article Snippet: A549 (ATCC CCL-185),
Techniques: Introduce, Selection, SDS Page, Western Blot, Control, Transduction, Variant Assay, Standard Deviation, Infection, Quantitative RT-PCR
Journal: ACS Omega
Article Title: Exploring SARS-CoV‑2 Spike RBD Pockets as Targets for Generic Drugs: A Combined Computational, Biophysical, and Biological Approach
doi: 10.1021/acsomega.5c05175
Figure Lengend Snippet: In vitro antiviral activity of selected compounds. (A) Antiviral activity against VSV pseudotyped with the S protein of Wuhan-Hu-1 and cellular toxicity for the indicated compounds in VeroE6 cells ( n = 3). (B) Virus production of SARS-CoV-2 infection by the indicated compounds at 20 μM or remdesivir (30 μM) in either A549-ACE2 or VeroE6-TMPRSS2 cells. (C) Antiviral activity of fingolimod against VSV pseudotyped with the indicated S protein ( n = 3). (D) Concentration reducing 50% of viral infection of VSV pseudotyped with the indicated S protein. All data represent the mean and standard error of 3 independent replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by two-tailed t test on log-transformed data.
Article Snippet: VeroE6-TMPRSS2 (Catalog No. JCRB1819, Japanese Collection of Research Bioresources), VeroE6 (kindly provided by Dr. Luis Enjuanes, CNB–CSIC, Spain), and
Techniques: In Vitro, Activity Assay, Virus, Infection, Concentration Assay, Two Tailed Test, Transformation Assay